Out of these enzymes, fructose 1,6-bisphosphatase (FBPase), a highly regulated enzyme that catalyzes the second to last step in gluconeogenesis [10,11], draws the attractiveness as a drug target to treat T2DM. Here, FBP1 is linked to type 2 diabetes mellitus.